• 1
    Mather K, Lteif A, Steinberg H, Baron A. Interactions between endothelin and nitric oxide in the regulation of vascular tone in obesity and diabetes. Diabetes 2004; 53: 20606.
  • 2
    Harrison DG. Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest 1997; 100: 21537.
  • 3
    Verma S, Anderson T. Fundamentals of endothelial function for the clinical cardiologist. Circulation 2002; 105: 5469.
  • 4
    Ludmer P, Selwyn A, Shook T et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 1986; 315: 104651.
  • 5
    Schalkwijk C, Stehouwer CD. Vascular complications in diabetes: the role of endothelial dysfunction. Clin Sci 2005; 109: 14359.
  • 6
    Calles-Escandon J, Cipolla M. Diabetes and endothelial dysfunction: a clinical perspective. Endocr Rev 2001; 22: 3652.
  • 7
    Taskinen M-R. Type 2 diabetes as a lipid disorder. Curr Mol Med 2005; 5: 297308.
  • 8
    Lundman P, Eriksson M, Schenck-Gustafsson K, Karpe F, Tornvall P. Transient triglyceridemia decreases vascular reactivity in young, healthy men without risk factors for coronary heart disease. Circulation 1997; 96: 32668.
  • 9
    Natali A, Toschi E, Baldeweg S et al. Haematocrit, type 2 diabetes, and endothelium-dependent vasodilatation of resistance vessels. Eur Heart J 2000; 21: 51520.
  • 10
    Goldfine A, Beckman J, Betensky R et al. Family history of diabetes is a major determinant of endothelial function. J Am Coll Cardiol 2006; 47: 245661.
  • 11
    Nyström T, Gutniak M, Zhang Q et al. Effects of glucagons-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol 2004; 287: E120915.
  • 12
    Caballero AE. Endothelial dysfunction in obesity and insulin resistance: a road to diabetes and heart disease. Obes Res 2003; 11: 127889.
  • 13
    Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 81320.
  • 14
    Williams SB, Goldfine AB, Timimi FK et al. Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation 1998; 97: 1695701.
  • 15
    Ueda S, Matsuoka H, Miyazaki H, Usui M, Okuda S, Imaizumi T. Tetrahydrobiopterin restores endothelial function in long-term smokers. J Am Coll Cardiol 2000; 35: 715.
  • 16
    Giugliano D, Marfella R, Coppola L et al. Vascular effects of acute hyperglycemia in humans are reversed by L-arginine. Evidence for reduced availability of nitric oxide during hyperglycemia. Circulation 1997; 95: 178390.
  • 17
    Fard A, Tuck CH, Donis JA et al. Acute elevations of plasma asymmetric dimethylarginine and impaired endothelial function in response to a high-fat meal in patients with type 2 diabetes. Arterioscler Thromb Vasc Biol 2000; 20: 203944.
  • 18
    Pickup J. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 2004; 27: 81323.
  • 19
    Trayhurn P. Endocrine and signalling role of adipose tissue: new perspectives on fat. Acta Physiol Scand 2005; 184: 28593.
  • 20
    Murdolo G, Smith U. The dysregulated adipose tissue: a connecting link between insulin resistance, type 2 diabetes mellitus and atherosclerosis. Nutr Metab Cardiovasc Dis 2006; 16 (Suppl 1): S358.
  • 21
    Graham T, Yang Q, Bluher M et al. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med 2006; 354: 255263.
  • 22
    Pellme F, Smith U, Funahashi T et al. Circulating adiponectin levels are reduced in nonobese but insulin-resistant first-degree relatives of type 2 diabetic patients. Diabetes 2003; 52: 11826.
  • 23
    Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 2005; 26: 43951.
  • 24
    Szmitko PE, Teoh H, Stewart D, Verma S. Adiponectin and cardiovascular disease. Am J Physiol Heart Circ Physiol 2007; 292: 165563.
  • 25
    Steppan C, Bailey S, Bhat S et al. The hormone resistin links obesity to diabetes. Nature 2001; 409: 30712.
  • 26
    Nagaev I, Smith U. Insulin resistance and type 2 diabetes are not related to resistin expression in human fat cells or skeletal muscle. Biochem Biophys Res Commun 2001; 285: 5614.
  • 27
    Reilly M, Lehrke M, Wolfe M, Rohatgi A, Lazar M, Rader D. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 2005; 111: 9329.
  • 28
    Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. Metabolic syndrome. A comprehensive perspective based on interactions between obesity diabetes and inflammation. Circulation 2005; 111: 144854.
  • 29
    Suwaidi J, Hamasaki S, Higano S, Nishimura R, Holmes D Jr, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000; 101: 94854.
  • 30
    Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001; 104: 26738.
  • 31
    Gokce N, Keaney JF Jr, Hunter L, Watkins M, Menzoian J, Vita J. Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function: a prospective study. Circulation 2002; 105: 156772.
  • 32
    Anderson T, Uehata A, Gerhard M et al. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 1995; 26: 123541.
  • 33
    Celermajer D, Sorensen K, Gooch V et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340: 11115.
  • 34
    Bots M, Westerink J, Rabelink T, De Koning E. Assessment of flow-mediated vasodilation (FMD) of the brachial artery: effects of technical aspects of the FMD measurement on the FMD response. Eur Heart J 2005; 26: 3638.
  • 35
    Wendelhag I, Fagerberg B, Hulthe J, Bokemark L, Wikstrand J. Endothelium-dependent flow-mediated vasodilatation, insulin resistance and the metabolic syndrome in 60-year-old men. J Intern Med 2002; 252: 30513.
  • 36
    Yki-Järvinen H. Insulin resistance and endothelial dysfunction. Best Pract Res Clin Endocrinol Metab 2003; 17: 41130.
  • 37
    Corretti M, Anderson T, Benjamin E et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002; 39: 25765.
  • 38
    Szmitko P, Wang C, Weisel R, De Almeida J, Anderson T, Verma S. New markers of inflammation and endothelial cell activation: Part I. Circulation 2003; 108: 191723.
  • 39
    Szmitko P, Wang C, Weisel R, Jeffries G, Anderson T, Verma S. Biomarkers of vascular disease linking inflammation to endothelial activation: Part II. Circulation 2003; 108: 20418.
  • 40
    Fadini GP, Sartore S, Albiero M et al. Number and function of endothelial progenitor cells as a marker of severity for diabetic vasculopati. Arterioscler Thromb Vasc Biol 2006; 26: 21406.
  • 41
    Scherrer U, Randin D, Vollenweider P, Vollenweider L, Nicod P. Nitric oxide release accounts for insulin’s vascular effects in humans. J Clin Invest 1994; 94: 25115.
  • 42
    Yki-Järvinen H, Utriainen T. Insulin-induced vasodilation: physiology or pharmacolgy? Diabetologia 1998; 41: 36979.
  • 43
    Steinberg H, Baron A. Insulin-mediated vasodilation: why one’s physiology could be the other’s pharmacology. Diabetologia 1999; 42: 4935.
  • 44
    Rattigan S, Clark M, Barrett E. Hemodynamic actions of insulin in rat skeletal muscle: evidence for capillary recruitment. Diabetes 1997; 46: 13818.
  • 45
    Baron A, Tarshoby M, Hook G et al. Interaction between insulin sensitivity and muscle perfusion on glucose uptake in human skeletal muscle Evidence for capillary recruitment. Diabetes 2000; 49: 76874.
  • 46
    Gudbjornsdottir S, Sjöstrand M, Strindberg L, Wahren J, Lönnroth P. Direct measurements of the permeability surface area for insulin and glucose in human skeletal muscle. J Clin Endocrinol Metab 2003; 88: 455964.
  • 47
    Kim J, Montagnani M, Kon Koh K, Quon M. Reciprocal relationships between insulin resistance and endothelial dysfunction. Molecular and pathophysiological mechanisms. Circulation 2006; 113: 1888904.
  • 48
    Jansson P-A, Pellme F, Hammarstedt A et al. A novel cellular marker of insulin resistance and early atherosclerosis in humans is related to impaired fat cell differentiation and low adiponectin. FASEB J 2003; 17: 143440.
  • 49
    Sandqvist M, Nyberg G, Hammarstedt A et al. Low adipocyte IRS-1 protein expression is associated with an increased arterial stiffness in non-diabetic males. Atherosclerosis 2005; 180: 11925.
  • 50
    Federici M, Pandolfi A, De Filippis A et al. G972R IRS-1 variant impairs insulin regulation of endothelial nitric oxide synthase in cultured human endothelial cells. Circulation 2004; 109: 399405.
  • 51
    Berg A, Scherer P. Adipose tissue, inflammation and cardiovascular disease. Circ Res 2005; 96: 93949.
  • 52
    Li X, Commane M, Jiang Z, Stark G. IL-1-induced NFkappa B and c-Jun N-terminal Kinase (JNK) activation diverge at IL-1 receptor associated kinase (IRAK). Proc Natl Acad Sci USA 2001; 98: 44615.
  • 53
    Anderson H, Rahmutula D, Gardner D. Tumor necrosis factor-alpha inhibits endothelial nitric-oxide synthase gene promoter activity in bovine aortic endothelial cells. J Biol Chem 2004; 279: 9639.
  • 54
    Min J, Kim Y, Kim S et al. TNF-related activation-induced cytokine enhances leukocyte adhesiveness: induction of ICAM-1 and VCAM-1 via TNF receptor-associated factor and protein kinase C-dependent NF-kappaB activation in endothelial cells. J Immunol 2005; 175: 53140.
  • 55
    Saito M, Ishimitsu T, Minami J, Ono H, Ohrui M, Matsuoka H. Relations of plasma high-sensitivity C-reactive protein to traditional cardiovascular risk factors. Atherosclerosis 2003; 167: 739.
  • 56
    Jialal I, Devaraj S, Venugopal S. C-reactive protein: risk marker or mediator in atherotrombosis? Hypertension 2004; 44: 611.
  • 57
    Venugopal S, Devaraj S, Yuhanna I, Shaul P, Jialal I. Demonstration that C-reactive protein decreases eNOS-expression and bioactivity in human aortic endothelial cells. Circulation 2002; 106: 143941.
  • 58
    Wang C, Li S, Weisel R et al. C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation 2003; 107: 178390.
  • 59
    Pasceri V, Cheng J, Willerson J, Yeh E. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 2001; 103: 25314.
  • 60
    Pasceri V, Willerson J, Yeh E. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000; 102: 21658.
  • 61
    Sjöholm Å, Nyström T. Endothelial inflammation in insulin resistance. Lancet 2005; 365: 6102.
  • 62
    Jiang Z, Lin Y, Clemont A et al. Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats. J Clin Invest 1999; 104: 44757.
  • 63
    Cusi K, Maezono K, Osman A et al. Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. J Clin Invest 2000; 105: 31120.
  • 64
    Jiang Z, Zhou Q, Chatterjee A et al. Endothelin-1 modulates insulin signaling through phosphatidylinositol 3-kinase pathway in vascular smooth muscle cells. Diabetes 1999; 48: 112030.
  • 65
    Strawbridge A, Elmendorf J. Endothelin-1 impairs glucose transporter trafficking via a membrane based mechanism. J Cell Biochem 2006; 97: 84956.
  • 66
    Engeli S, Negrel R, Sharma A. Physiology and pathophysiology of the adipose tissue renin-angiotensin system. Hypertension 2000; 35: 12707.
  • 67
    Yusuf S, Gerstein H, Hoogwerf B et al. Ramipril and the development of diabetes. JAMA 2001; 286: 18825.
  • 68
    Folli F, Kahn CR, Hansen H, Bouchie J, Feener E. Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk. J Clin Invest 1997; 100: 215869.
  • 69
    Rajagopalan S, Kurz S, Munzel T et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 1996; 97: 191623.
  • 70
    Pastore L, Tessitore A, Martinotti S et al. Angiotensin II stimulates intercellular adhesion molecule-1 (ICAM-1) expression by human vascular endothelial cells and increases soluble ICAM-1 release in vivo. Circulation 1999; 100: 164652.
  • 71
    Desideri G, Ferri C, Bellini C, De Mattia G, Santucci A. Effects of ACE inhibition on spontaneous and insulin-stimulated endothelin-1 secretion: in vitro and in vivo studies. Diabetes 1997; 46: 816.
  • 72
    Velloso L, Folli F, Sun X, White M, Saad M, Kahn CR. Cross-talk between the insulin and angiotensin signaling systems. Proc Natl Acad Sci USA 1996; 93: 124905.
  • 73
    Ceriello A, Assaloni R, Da Ros R et al. Effect of atorvastatin and irbesartan alone and in combination on postprandial endothelial dysfunction, oxidative stress, and inflammation in type 2 diabetic patients. Circulation 2005; 111: 251824.
  • 74
    Laakso M, Edelman S, Brechtel G, Baron A. Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man. A novel mechanism for insulin resistance. J Clin Invest 1990; 85: 184452.
  • 75
    Ferrannini E, Smith J, Cobelli C, Toffolo G, Pilo A, DeFronzo R. Effects of insulin on the distribution and disposition of glucose in man. J Clin Invest 1985; 76: 35764.
  • 76
    Cersosimo E, DeFronzo R. Insulin resistance and endothelial dysfunction:the road map to cardiovascular diseases. Diabetes Metab Res Rev 2006; 22: 42336.
  • 77
    Steinberg H, Chaker H, Leaming R, Johnson A, Brechtel G, Baron A. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 1996; 97: 260110.
  • 78
    Coggins M, Lindner J, Rattigan S et al. Physiologic hyperinsulinemia enhances human skeletal muscle perfusion by capillary recruitment. Diabetes 2001; 50: 268290.
  • 79
    Sjöstrand M, Gudbjörnsdottir S, Holmäng A, Lönn L, Strindberg L, Lönnroth P. Delayed transcapillary transport of insulin to muscle interstitial fluid in obese subjects. Diabetes 2002; 51: 27428.
  • 80
    Jansson P-A, Fowelin J, Von Schenck H, Smith U, Lönnroth P. Measurement by microdialysis of the insulin concentration in subcutaneous interstitial fluid. Importance of the endothelial barrier for insulin. Diabetes 1993; 42: 146973.
  • 81
    Baron A, Steinberg H, Chaker H, Leaming R, Johnson A, Brechtel G. Insulin-mediated skeletal muscle vasodilation contributes to both insulin sensitivity and responsiveness in lean humans. J Clin Invest 1995; 96: 78692.
  • 82
    Castillo C, Bogardus C, Bergman R, Thuillez P, Lillioja S. Interstitial insulin concentrations determine glucose uptake rates but not insulin resistance in lean and obese men. J Clin Invest 1994; 93: 106.
  • 83
    Thorand B, Baumert J, Chambless L et al. Elevated markers of endothelial dysfunction predict type 2 diabetes mellitus in middle-aged men and women from the general population. Arterioscler Thromb Vasc Biol 2006; 26: 398405.
  • 84
    Festa A, D’Agostino R Jr, Tracy R, Haffner S. Elevated levels of acute-phase proteins and plamonogen activator inhibitor-1 predict the development of type 2 diabetes: the Insulin Resistance Atherosclerosis Study. Diabetes 2002; 51: 11317.
  • 85
    Rossi R, Cioni E, Nuzzo A, Origliani G, Modena M. Endothelial-dependent vasodilation and incicence of type 2 diabetes in a population of healthy postmenopausal women. Diabetes Care 2005; 28: 7027.
  • 86
    Meigs J, O´Donnell CJ, Tofler GH et al. Hemostatic markers of endothelial dysfunction and risk of incident type 2 diabetes. The Framingham Offspring Study. Diabetes 2006; 55: 5307.